Despite ongoing efforts to eradicate racism, it persists globally, negatively affecting education, mental health, community relations, and economic development. Every behavior analyst can, and should, contribute to the reduction of racism in some way. Unfortunately, little behavior-analytic research exists to guide us. This article proposes ways that members of our scientific community can learn about racism from a behavioral perspective, extend experimental analyses of prejudice, and intervene to reduce racism in varied settings. It describes both traditional behavior-analytic and functionalcontextualist accounts of racism and summarizes the small amount of related empirical and applied research. The review suggests that combining traditional behavior-analytic methods with acceptance and commitment training techniques may attenuate racism more effectively. The article ends with a call to collaborate around this globally important issue-and to do more to reduce racism.

AimDolutegravir is the newest integrase inhibitor approved for HIV treatment and has demonstrated potent antiviral activity in patient populations with a broad range of treatment experience. This analysis aimed to characterize the population pharmacokinetics of dolutegravir in treatment-naive patients and to evaluate the influence of patient covariates.MethodsA population pharmacokinetic model was developed using a non-linear mixed effect modelling approach based on data from 563 HIV-infected, treatment-naive adult patients in three phase 2/3 trials who received dolutegravir (ranging from 10–50 mg once daily) alone or in combination with abacavir/lamivudine or tenofovir/emtricitabine.ResultsThe pharmacokinetics of dolutegravir were adequately described by a linear one compartment model with first order absorption, absorption lag time and first order elimination. Population estimates for apparent clearance, apparent volume of distribution, absorption rate constant and absorption lag time were 0.901 l h–1, 17.4 l, 2.24 h−1, and 0.263 h, respectively. Weight, smoking status, age and total bilirubin were predictors of clearance, weight was a predictor of volume of distribution and gender was a predictor of bioavailability. However, the magnitude of the effects of these covariates on steady-state dolutegravir plasma exposure was relatively small (<32%) and was not considered clinically significant. Race/ethnicity, HBV/HCV co-infection, CDC classification, albumin, creatinine clearance, alanine aminotransferase or aspartate aminotransferase did not influence the pharmacokinetics of dolutegravir in this analysis.ConclusionsA population model that adequately characterizes dolutegravir pharmacokinetics has been developed. No dolutegravir dose adjustment by patient covariates is necessary in HIV-infected treatment-naive patients.

Previous research has shown that providing choices may result in an increase in appropriate behavior and a decrease in inappropriate behavior; however, the process by which choice results in a behavior change is unknown. In the current study, we replicated and extended previous research by determining the prevalence of preference for choice in a large number of children and evaluating whether a history of differential outcomes associated with choice and no choice resulted in changes in preference for those conditions. Results from Study 1 showed that the majority of participants preferred choice contexts when child choice and experimenter choice resulted in identical outcomes. In Study 2, participants' preferences were altered when child choice and experimenter choice resulted in differential outcomes, but a history with differential outcomes did not produce a reliable and durable effect on selections.

Abstract. The COVID-19 pandemic has affected all societies worldwide. The heightened levels of stress that accompanied the crisis were also expected to affect parenting in many families. Since it is known that high levels of stress in the parenting domain can lead to a condition that has severe consequences for health and well-being, we examined whether the prevalence of parental burnout in 26 countries (9,923 parents; 75% mothers; mean age 40) increased during COVID-19 compared to few years before the pandemic. In most (but not all) countries, analyses showed a significant increase in the prevalence of parental burnout during the pandemic. The results further revealed that next to governmental measures (e.g., number of days locked down, homeschooling) and factors at the individual and family level (e.g., gender, number of children), parents in less (vs. more) indulgent countries suffered more from parental burnout. The findings suggest that stricter norms regarding their parenting roles and duties in general and during the pandemic in particular might have increased their levels of parental burnout.